JPM26: Bayer evades patent cliff in a way it may not be able to repeat
Secondary US filings for Bayer assets cannot be relied on again to face future patent cliffs, demanding focus on early-stage R&D.
JPM26: BioNTech gears up for multiproduct oncology status by 2030
JPM26: Pfizer’s Metsera deal supercharges its obesity strategy
JPM26: 2025 a “breakout year” for rare disease biotechs
JPM26: J&J leans on immunology launches to fuel annual growth
JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery
Analysis
View More
Themes
View MoreEli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
The partnership is the latest in a long line of AI-centric projects in drug discovery and development.
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry
GlobalData Reports
View more
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?
Trump blames Covid-19 drugmakers for fuelling CDC turmoil